Spyre Therapeutics Rises on Narrower-Than-Expected 4Q Loss

Dow Jones

Yesterday

By Elias Schisgall

Shares of Spyre Therapeutics rose after the biotechnology company's fourth-quarter loss came in narrower than Wall Street expectations.

Shares were trading up 9.9%, at $41.54, midday Friday. The stock is up 27% over the past year.

The company on Thursday reported a loss of $62.5 million, or 70 cents a share, compared with a loss of $52.3 million, or 81 cents a share, a year earlier.

Analysts surveyed by FactSet were expecting a loss of 71 cents a share.

The Waltham, Mass., company, which is developing treatments for inflammatory-bowel disease and rheumatic diseases, didn't post any sales during the fourth quarter.

It said it expects readouts from two Phase 2 trials this year.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

February 20, 2026 12:26 ET (17:26 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2613929982"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613929982\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613929982?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-21 01:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613929982","market":"sg","top_or_hot":-1,"title":"Spyre Therapeutics Rises on Narrower-Than-Expected 4Q Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a> rose after the biotechnology company's fourth-quarter loss came in narrower than Wall Street expectations. \n</p>\n<p>\n  Shares were trading up 9.9%, at $41.54, midday Friday. The stock is up 27% over the past year. \n</p>\n<p>\n  The company on Thursday reported a loss of $62.5 million, or 70 cents a share, compared with a loss of $52.3 million, or 81 cents a share, a year earlier. \n</p>\n<p>\n  Analysts surveyed by FactSet were expecting a loss of 71 cents a share. \n</p>\n<p>\n  The Waltham, Mass., company, which is developing treatments for inflammatory-bowel disease and rheumatic diseases, didn't post any sales during the fourth quarter. \n</p>\n<p>\n  It said it expects readouts from two Phase 2 trials this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 20, 2026 12:26 ET (17:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spyre Therapeutics Rises on Narrower-Than-Expected 4Q Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpyre Therapeutics Rises on Narrower-Than-Expected 4Q Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-21 01:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a> rose after the biotechnology company's fourth-quarter loss came in narrower than Wall Street expectations. \n</p>\n<p>\n  Shares were trading up 9.9%, at $41.54, midday Friday. The stock is up 27% over the past year. \n</p>\n<p>\n  The company on Thursday reported a loss of $62.5 million, or 70 cents a share, compared with a loss of $52.3 million, or 81 cents a share, a year earlier. \n</p>\n<p>\n  Analysts surveyed by FactSet were expecting a loss of 71 cents a share. \n</p>\n<p>\n  The Waltham, Mass., company, which is developing treatments for inflammatory-bowel disease and rheumatic diseases, didn't post any sales during the fourth quarter. \n</p>\n<p>\n  It said it expects readouts from two Phase 2 trials this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 20, 2026 12:26 ET (17:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2613929982","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613929982","pubTimestamp":1771608360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Spyre Therapeutics rose after the biotechnology company's fourth-quarter loss came in narrower than Wall Street expectations.Shares were trading up 9.9%, at $41.54, midday Friday. The stock is up 27% over the past year.The company on Thursday reported a loss of $62.5 million, or 70 cents a share, compared with a loss of $52.3 million, or 81 cents a share, a year earlier.Analysts surveyed by FactSet were expecting a loss of 71 cents a share.The Waltham, Mass., company, which is developing treatments for inflammatory-bowel disease and rheumatic diseases, didn't post any sales during the fourth quarter.It said it expects readouts from two Phase 2 trials this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SYRE":"SPYRE THERAPEUTICS INC","BK4007":"制药","LENZ":"Therapeutics","BK4539":"次新股"},"translate_title":"Spyre Therapeutics因第四季度亏损窄于预期而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"SYRE":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Spyre Therapeutics rose after the biotechnology company's fourth-quarter loss came in narrower than Wall Street expectations. \n\n\n  Shares were trading up 9.9%, at $41.54, midday Friday. The stock is up 27% over the past year. \n\n\n  The company on Thursday reported a loss of $62.5 million, or 70 cents a share, compared with a loss of $52.3 million, or 81 cents a share, a year earlier. \n\n\n  Analysts surveyed by FactSet were expecting a loss of 71 cents a share. \n\n\n  The Waltham, Mass., company, which is developing treatments for inflammatory-bowel disease and rheumatic diseases, didn't post any sales during the fourth quarter. \n\n\n  It said it expects readouts from two Phase 2 trials this year. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 20, 2026 12:26 ET (17:26 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}